Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: Implications for the treatment of hepatitis C

Antiviral Chemistry and Chemotherapy

Volumn 15, Issue 3, 2004, Pages 141-151

  Whitby, Kevin ^a   Taylor, Debra ^b   Patel, Dipa ^b   Ahmed, Parvin ^b   Tyms, A Stanley ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

6 O butanoyl castanospermine; Celgosivir; HCV; Hepatitis C virus; glucosidase I inhibitors

Indexed keywords

1 DEOXYNOJIRIMYCIN; ALPHA GLUCOSIDASE INHIBITOR; ALPHA INTERFERON; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; N NONYLDEOXYNOJIRIMYCIN; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE DIARRHEA VIRUS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEPATITIS C; HEPATITIS C VIRUS; IC 50; NONHUMAN; PESTIVIRUS; PRIORITY JOURNAL; PROTEIN FOLDING; VIRUS ENVELOPE; VIRUS GENOME; VIRUS PARTICLE; VIRUS PLAQUE; VIRUS REPLICATION;

EID: 2942700289     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020401500304     Document Type: Article

References (25)

1. Ahmed SP, Nash RJ, Bridges CG, Taylor DL, Kang MS, Porter EA & Tyms AS (1995) Antiviral activity and metabolism of the castanospermine derivative MDL 28574, in cells infected with herpes simplex virus type 2. Biochemical & Biophysical Research Communications 208:267-273.
2. Berenbaum MC (1989) What is synergy? Pharmacology Review 41:93-141.
3. Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, Blumberg B & Dwek RA (1994) Secretion of human hepatitis B virus is inhibited by the imino sugar n-butyldeoxynojirimycin. Proceedings of the National Academy of Sciences, USA 1994. 91:2235-2239.
4. Branza-Nichita N, Durantel D, Carrouee-Durantel S, Dwek RA & Zitzman N (2001) Antiviral effect of n-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. Journal of Virology 75:3527-3536.
5. Brennan TM, Taylor DL, Bridges GC, Leyda J & Tyms AS (1995) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Research 26:173-187.
6. Chou T-C & Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulations 22:27-55.
7. Choukhi A, Ung S, Wychowski C & Dubuisson J (1998) Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. Journal of Virology 72:3851-3858.
8. Courageot M-P, Frenkiel M-P, Dos Santos CD, Deubel V & Desprès P (2000) α-Glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic recticulum. Journal of Virology 74:564-572.
9. Ellgaard L, Molinari M & Helenius A (1999) Setting the standards: quality control in the secretory pathway. Science 1999. 286:1882-1888.
10. Helenius A & Aebi M (2001) Intracellular functions of n-linked glycans. Science 2001. 291:2364-2369.
11. Lu X, Mehta A, Dwek R, Butters & Block T (1995) Evidence that n-linked glycosylation is necessary for hepatitis B virus secretion. Virology 213:660-665.
12. Mackenzie JM & Westaway EG (2001) Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. Journal of Virology 75:10787-10799.
13. McHutchison JG & Patel K (2002) Future therapy of hepatitis C. Hepatology 36:S245-S252.
14. Merola M, Brazzoli M, Cocchiarella F, Heile JM, Helenius A, Weiner AJ, Houghton M & Abrignani S (2001) Folding of hepatitis C virus e1 glycoprotein in a cell-free system. Journal of Virology 75:11205-11217.
15. Mertes G (2001) Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Research & Clinical Practice 52:193-204.
16. Ouzounov S, Mehta A, Dwek RA, Block TM & Jordan R (2002) The combination of interferon alpha-2β and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. Antiviral Research 55:425-435.
17. Pan YT, Ghidoni J & Elbein AD (1993) The effects of castanospermine and swainsonine on the activity and synthesis of intestinal sucrase. Archives of Biochemistry & Biophysics 303:134-144.
18. Rice CM (1996) Flaviviridae: the viruses and their replication. Fields Virology. 3rd edition. Philadelphia:Lippincott, pp. 931-959.
19. Stuyver LJ, Lostia S, Patterson SE, Clark JL, Watanabe KA, Otto MJ & Pankiewicz KW (2002) Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents. Antiviral Chemistry & Chemotherapy 13:345-352.
20. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ & Schinazi RF (2003) Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrobial Agents & Chemotherapy 47:244-254.
21. Suhnel J (1990) Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Research 13:23-40.
22. Taylor DL, Fellows LE, Farrar GH, Nash R., Taylor-Robinson D, Mobberley MA, Ryder TA, Jeffries DJ & Tyms AS (1988) Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis. Antiviral Research 10:11-26.
23. Taylor DL, Kang MS, Brennan TM, Bridges CG, Sunkara PS & Tyms AS (1994) Inhibition of α-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrobial Agents & Chemotherapy 38:1780-1787.
24. Taylor DL, Sunkara PS, Lui PS, Kang MS, Bowlin TL & Tyms AS (1991) 6-O-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIV. AIDS 5:693-698
25. WHO (2000) Hepatitis C. WHO Fact Sheet Number 164.